HYLAB, Laboratory of Clinical Physiology and Exercise, Grenoble, France.
Int J Chron Obstruct Pulmon Dis. 2010 Apr 7;5:57-71. doi: 10.2147/copd.s7404.
Exercise tolerance is an important parameter in patients with COPD and a primary goal of treatment is to reduce dyspnea to facilitate physical activities and improve health-related quality of life. This review examines the link between expiratory flow limitation and dyspnea to explain the rationale for the use of bronchodilators and review the characteristics of different types of exercise tests, with specific focus on which tests are likely to show a response to bronchodilators. An earlier literature search of studies published up to 1999 assessed the effects of bronchodilatort therapy on dypsnea and exercise tolerance among patients with COPD. This current review examines the clinical evidence published since 1999. Thirty-one randomized studies of exercise tolerance associated with short- and long-acting beta(2)-agonists and anticholinergics were identified. Evidence for the efficacy of bronchodilators in enhancing exercise capacity is often contradictory and possibly depends on the exercise test and study methodology. However, further studies should confirm the benefit of long-acting bronchodilators in improving spontaneous everyday physical activities.
运动耐量是 COPD 患者的一个重要参数,治疗的主要目标是减轻呼吸困难,以促进身体活动和提高健康相关的生活质量。这篇综述探讨了呼气流量受限与呼吸困难之间的关系,解释了使用支气管扩张剂的基本原理,并回顾了不同类型运动试验的特点,特别关注哪些试验可能对支气管扩张剂有反应。早期对截至 1999 年发表的研究的文献检索评估了支气管扩张剂治疗对 COPD 患者呼吸困难和运动耐量的影响。本综述审查了自 1999 年以来发表的临床证据。确定了 31 项与短效和长效β2-激动剂和抗胆碱能药物相关的运动耐量的随机研究。支气管扩张剂在增强运动能力方面的疗效证据往往相互矛盾,这可能取决于运动试验和研究方法。然而,进一步的研究应该证实长效支气管扩张剂在改善日常自发性身体活动方面的益处。